Atropine Sulfate (Atropine Sulfate) Patent Expiration, LOE Window & CMS Spending

Atropine Sulfate (Atropine Sulfate) by Pfizer: Off-Patent Genericized (AB Competition), 17 AB generics, $16.9M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN021146 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors17
2024 CMS Total Public Spend$16.9M
2024 Medicare Part D Spend$8.9M
2024 Medicaid Spend$7.9M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 77.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.